Elite Pharma Inc (ELTP) 0.1711 $ELTP Elite Anno
Post# of 273254
Posted On: 09/22/2016 7:12:27 PM
Elite Pharma Inc (ELTP) 0.1711 $ELTP
Elite Announces Development and License Agreement with SunGen Pharma LLC
GlobeNewswire - Mon Aug 29, 8:01AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement ("Agreement" with SunGen Pharma, LLC ("SunGen" to collaborate to develop and commercialize four generic pharmaceutical products.
Elite Pharmaceuticals files ANDA to Market Generic Percocet
GlobeNewswire - Wed Aug 10, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of Percocet (oxycodone hydrochloride and acetaminophen, USP CII) 5 mg, 7.5 mg and 10 mg tablets with 325 mg of acetaminophen. Percocet is a combination medication and is used to help relieve moderate to severe pain.
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information
GlobeNewswire - Tue Aug 09, 3:20PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the three months ended June 30, 2016, the first quarter of its 2017 fiscal year.
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
GlobeNewswire - Wed Jun 15, 3:19PM CDT
Revenues Increased 150%
Elite Pharmaceuticals to Present SequestOx(TM) Data at the American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Mon May 09, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today it will present data for SequestOx(TM) (ELI-200) at the American Pain Society 35 Annual Scientific Meeting being held in Austin, Texas, USA, May 11 - 14, 2016. The abstract, is entitled Pharmacodynamic data assessing the abuse potential of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration.
Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
GlobeNewswire - Wed May 04, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to its board effective April 28, 2016.
$200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore
ACCESSWIRE - Wed Feb 10, 7:31AM CST
MIAMI, FL / ACCESSWIRE / February 10, 2016 / $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore. CD International Enterprises, Inc. (OTCPK: CDII), a U.S.-based company that sources industrial commodities just announced that a $200 million order, over a 24-month period was placed with its wholly owned subsidiary Capital Resources Management Corporation.
CLF: 6.23 (+0.06)
Elite Pharmaceuticals generates higher consolidated revenues of USD2.2m for Q3 fiscal 2016
M2 - Wed Feb 10, 4:58AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Tuesday that it recorded consolidated revenues of USD2.2m for the quarter ended 31 December 2015, the third quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
GlobeNewswire - Tue Feb 09, 3:32PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2016 Financial Results on February 10, 2016
GlobeNewswire - Fri Feb 05, 11:43AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its third quarter financial results will be released on Tuesday, February 9, 2016. Following the announcement, Elite's management will host a live conference call on Wednesday, February 10 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Shareholders may submit questions for management in advance of the call.
Analyst Insights Behind Price Movement - Analyst Research on CD International Enterprises, Elite Pharmaceuticals, Anglo American and Pilot Gold
ACCESSWIRE - Mon Feb 01, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Elite Pharmaceuticals Inc. (OTC: ELTP), Anglo American PLC (OTC: NGLOY) and Pilot Gold Inc. (OTC: PLGTF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Traders Look to Upside - Analyst Research on SandRidge Energy, Elite Pharmaceuticals, Dyadic International and Accretive Health
ACCESSWIRE - Thu Jan 21, 8:34AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SandRidge Energy Inc. (OTC: SDOC), Elite Pharmaceuticals Inc. (OTC: ELTP), Dyadic International Inc. (OTC: DYAI) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SD: 0.15 (-0.02)
Elite Pharmaceuticals awarded waiver fee for ELI-200 NDA under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act
M2 - Fri Jan 15, 5:10AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Thursday that it has received a waiver of the application fee required for the filing of a New Drug Application (NDA) for ELI-200 from the US Food and Drug Administration (FDA).
Elite Pharmaceuticals reports changes in board
M2 - Thu Jan 14, 6:27AM CST
Elite Pharmaceuticals (OTCBB:ELTP) said on Wednesday that Jerry Treppel has stepped down as its chairman and as a member of the board of directors with effect from 11 January 2016, to pursue other opportunities.
FDA Approves Waiver of NDA Filing Fee for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 3:52PM CST
The United State Food and Drug Administration ("FDA" granted Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) a waiver of the application fee required for the filing of a New Drug Application (NDA). Under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act the FDA may grant a waiver of the $2,335,200 NDA application fee for the first human drug application that a small business submits for review.
Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 8:25AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) announced that Jerry Treppel has resigned as the Company's Chairman and as a member of the Board of Directors, effective January 11, 2016, to pursue other opportunities.
Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.
Equity Market Movement at a Glance - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Ekso Bionics Holdings, and Medical Marijuana
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO),Elite Pharmaceuticals Inc. (OTC: ELTP), Ekso Bionics Holdings Inc. (OTC: EKSO) and Medical Marijuana Inc. (OTC: MJNA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.55 (-0.08), EKSO: 3.64 (+0.01)
The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.55 (-0.08), EKSO: 3.64 (+0.01), BBSI: 48.00 (+0.13)
Elite Announces Development and License Agreement with SunGen Pharma LLC
GlobeNewswire - Mon Aug 29, 8:01AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced it has entered into a Development and License Agreement ("Agreement" with SunGen Pharma, LLC ("SunGen" to collaborate to develop and commercialize four generic pharmaceutical products. Elite Pharmaceuticals files ANDA to Market Generic Percocet
GlobeNewswire - Wed Aug 10, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of Percocet (oxycodone hydrochloride and acetaminophen, USP CII) 5 mg, 7.5 mg and 10 mg tablets with 325 mg of acetaminophen. Percocet is a combination medication and is used to help relieve moderate to severe pain. Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2017 and Provides Conference Call Information
GlobeNewswire - Tue Aug 09, 3:20PM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results for the three months ended June 30, 2016, the first quarter of its 2017 fiscal year. Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2016 and Provides Conference Call Information
GlobeNewswire - Wed Jun 15, 3:19PM CDT
Revenues Increased 150%
Elite Pharmaceuticals to Present SequestOx(TM) Data at the American Pain Society 35th Annual Scientific Meeting
GlobeNewswire - Mon May 09, 6:30AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today it will present data for SequestOx(TM) (ELI-200) at the American Pain Society 35 Annual Scientific Meeting being held in Austin, Texas, USA, May 11 - 14, 2016. The abstract, is entitled Pharmacodynamic data assessing the abuse potential of a novel abuse deterrent oxycodone formulation (ELI-200) compared to oxycodone immediate release, oral intact ELI-200, and placebo in healthy, non-dependent recreational opioid users following intranasal administration. Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
GlobeNewswire - Wed May 04, 7:00AM CDT
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to its board effective April 28, 2016. $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore
ACCESSWIRE - Wed Feb 10, 7:31AM CST
MIAMI, FL / ACCESSWIRE / February 10, 2016 / $200 Million Order, Industrial Commodities Co. Strikes Gold in Iron Ore. CD International Enterprises, Inc. (OTCPK: CDII), a U.S.-based company that sources industrial commodities just announced that a $200 million order, over a 24-month period was placed with its wholly owned subsidiary Capital Resources Management Corporation.
CLF: 6.23 (+0.06)
Elite Pharmaceuticals generates higher consolidated revenues of USD2.2m for Q3 fiscal 2016
M2 - Wed Feb 10, 4:58AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Tuesday that it recorded consolidated revenues of USD2.2m for the quarter ended 31 December 2015, the third quarter of its 2016 fiscal year.
Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
GlobeNewswire - Tue Feb 09, 3:32PM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter of its 2016 fiscal year. Elite Pharmaceuticals, Inc. to Host Conference Call to Discuss 3rd Quarter 2016 Financial Results on February 10, 2016
GlobeNewswire - Fri Feb 05, 11:43AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announced today that its third quarter financial results will be released on Tuesday, February 9, 2016. Following the announcement, Elite's management will host a live conference call on Wednesday, February 10 at 11:30 AM EST to discuss the company's financial and operating results and provide a general business update. Company executives will conduct a question and answer session following their remarks. Shareholders may submit questions for management in advance of the call. Analyst Insights Behind Price Movement - Analyst Research on CD International Enterprises, Elite Pharmaceuticals, Anglo American and Pilot Gold
ACCESSWIRE - Mon Feb 01, 7:25AM CST
NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International Enterprises Inc. (OTC: CDII), Elite Pharmaceuticals Inc. (OTC: ELTP), Anglo American PLC (OTC: NGLOY) and Pilot Gold Inc. (OTC: PLGTF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Traders Look to Upside - Analyst Research on SandRidge Energy, Elite Pharmaceuticals, Dyadic International and Accretive Health
ACCESSWIRE - Thu Jan 21, 8:34AM CST
NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SandRidge Energy Inc. (OTC: SDOC), Elite Pharmaceuticals Inc. (OTC: ELTP), Dyadic International Inc. (OTC: DYAI) and Accretive Health Inc. (OTC: ACHI). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
SD: 0.15 (-0.02)
Elite Pharmaceuticals awarded waiver fee for ELI-200 NDA under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act
M2 - Fri Jan 15, 5:10AM CST
Pharmaceutical company Elite Pharmaceuticals (OTCBB:ELTP) stated on Thursday that it has received a waiver of the application fee required for the filing of a New Drug Application (NDA) for ELI-200 from the US Food and Drug Administration (FDA).
Elite Pharmaceuticals reports changes in board
M2 - Thu Jan 14, 6:27AM CST
Elite Pharmaceuticals (OTCBB:ELTP) said on Wednesday that Jerry Treppel has stepped down as its chairman and as a member of the board of directors with effect from 11 January 2016, to pursue other opportunities.
FDA Approves Waiver of NDA Filing Fee for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 3:52PM CST
The United State Food and Drug Administration ("FDA"
granted Elite Pharmaceuticals, Inc. ("Elite" or the "Company" (OTCBB:ELTP) a waiver of the application fee required for the filing of a New Drug Application (NDA). Under section 736(d)(1)(E) of the Federal Food, Drug and Cosmetic Act the FDA may grant a waiver of the $2,335,200 NDA application fee for the first human drug application that a small business submits for review. Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals
GlobeNewswire - Wed Jan 13, 8:25AM CST
Elite Pharmaceuticals, Inc. ("Elite" or the "Company"
(OTCBB:ELTP) announced that Jerry Treppel has resigned as the Company's Chairman and as a member of the Board of Directors, effective January 11, 2016, to pursue other opportunities. Five Small Cap Stocks Experiencing Huge Growth Potential
ACCESSWIRE - Fri Dec 11, 7:18AM CST
DELRAY BEACH, FL / ACCESSWIRE / December 11, 2015 / In today's quickly evolving market, small cap stocks increasingly profile as a viable investment for those with a higher risk tolerance. While the global market stirs, newer, smaller companies continue to claim larger portions of industry shares, and surprising names begin to surface as possible leaders in their respective fields.
Equity Market Movement at a Glance - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Ekso Bionics Holdings, and Medical Marijuana
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO),Elite Pharmaceuticals Inc. (OTC: ELTP), Ekso Bionics Holdings Inc. (OTC: EKSO) and Medical Marijuana Inc. (OTC: MJNA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.55 (-0.08), EKSO: 3.64 (+0.01)
The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 0.55 (-0.08), EKSO: 3.64 (+0.01), BBSI: 48.00 (+0.13)
(0)
(0)Scroll down for more posts ▼